Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
Iradimed Corporation (IRMD) provides essential medical technologies for MRI environments through its innovative devices. This news hub offers investors and healthcare professionals timely updates on product developments, financial performance, and operational milestones.
Access official press releases and verified news about IRMD's MRI-compatible infusion systems, patient monitoring solutions, and regulatory achievements. Stay informed about quarterly earnings, partnership announcements, and clinical validation studies that demonstrate the company's market leadership.
Key updates include FDA clearances, international expansion efforts, and technological enhancements to the company's non-magnetic device ecosystem. Content is organized chronologically showcase IRMD's progress in improving MRI safety standards while maintaining financial transparency.
Bookmark this page for direct access to primary source materials from Iradimed Corporation. Check regularly for updates on innovations addressing critical needs in diagnostic imaging and patient care during magnetic resonance procedures.
Iradimed Corporation (NASDAQ: IRMD) has received FDA 510(k) clearance for its MRidium® 3870 IV Infusion Pump System, a next-generation MRI-compatible infusion pump. The device maintains Iradimed's unique position as the world's only provider of non-magnetic MRI infusion pumps since 2005. The new system features a non-magnetic ultrasonic pump motor, non-interfering RF emissions, and an enhanced touchscreen interface.
Key features include the ability to operate independently or as a four-channel system, and a modern drug library solution supporting multiple patient care areas. The company plans to begin deployment to select healthcare facilities in Q4 2025, with full commercial distribution ramping throughout 2026.
IRADIMED (NASDAQ: IRMD) reported strong Q1 2025 financial results with record revenue of $19.5 million, up 11% year-over-year. The company achieved GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42, representing increases of 16% and 17% respectively. The Board declared a quarterly dividend of $0.17 per share, payable on May 30, 2025.
The company maintained its full-year 2025 guidance, expecting revenue between $78.0-82.0 million and GAAP diluted EPS of $1.55-1.65. For Q2 2025, IRADIMED projects revenue of $19.7-19.9 million. Domestic sales represented 82% of total revenue, and gross profit margin remained steady at 76.1%. The company's new manufacturing facility is on track for completion in July 2025, with approximately $3.0 million in remaining construction costs.
IRADIMED (NASDAQ: IRMD) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will release its Q1 2025 financial results before market opening on Monday, May 5, 2025. Management will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results and address questions.
Interested participants can register for the conference call through a provided link. Upon registration, they will receive a dial-in number, unique pin, and instructions. The call will also be available via live webcast on the company's investor relations website, with a recording made available afterward.
IRADIMED (NASDAQ: IRMD) has scheduled its first quarter 2025 financial results announcement for Friday, May 5, 2025, before market opening. The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results and address questions.
Interested participants can register for the conference call through a provided link, after which they will receive dial-in details and a unique pin. The call will also be available via live webcast on the company's investor relations website, with a recording accessible afterward.
IRADIMED (NASDAQ: IRMD) has announced its participation in the upcoming 37th Annual Roth Conference. The event will take place on March 17 and 18, 2025, at the Laguna Cliffs Marriott in Dana Point, CA.
The company will be represented by CFO Jack Glenn and CCO Jeff Chiprin, who will conduct one-on-one meetings with investors during the conference.
IRADIMED (NASDAQ: IRMD) reported record Q4 2024 revenue of $19.4 million, up 11% year-over-year, marking its fourteenth consecutive quarter of revenue growth. The company achieved Q4 GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.44.
For full-year 2024, revenue reached $73.2 million, a 12% increase from 2023, with GAAP diluted EPS of $1.50 and non-GAAP diluted EPS of $1.66. The company increased its quarterly dividend to $0.17 per share from $0.15.
Looking ahead to 2025, IRADIMED projects revenue between $78.0-82.0 million, with GAAP diluted EPS of $1.55-1.65 and non-GAAP diluted EPS of $1.71-1.81. Q1 2025 guidance indicates revenue of $19.2-19.4 million with GAAP diluted EPS of $0.35-0.39.
IRADIMED (NASDAQ: IRMD) has announced its upcoming fourth quarter and full year 2024 financial results conference call, scheduled for February 13, 2025. The company will release its financial results before the market opens, followed by a conference call at 11:00 a.m. Eastern Time.
Management will host the call to discuss results and answer questions. Interested participants can register online to receive dial-in information and a unique pin. The call will be available in real-time via the internet on the company's investor relations website, and a recording will be made available afterward.
IRADIMED (NASDAQ: IRMD) has reported preliminary unaudited record revenues for Q4 and full-year 2024. The company expects Q4 2024 revenue between $19.2 million to $19.4 million, representing 10-11% year-over-year growth and 5-6% sequential growth. Full-year 2024 revenue is anticipated to be between $73.1 million to $73.3 million, showing 11-12% growth compared to $65.6 million in 2023.
The company achieved its fourteenth consecutive quarter of record-breaking revenues, with Q4 2024 marking their highest quarterly revenue to date. Orders booked in Q4 exceeded shipments, creating a robust backlog for 2025. The company expects increasing product demand to continue throughout 2025.
IRADIMED (NASDAQ: IRMD), a pioneer in MRI-compatible medical devices and exclusive provider of non-magnetic IV infusion pump systems, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Roger Susi and CFO Jack Glenn will deliver the company presentation on Wednesday, January 15, 2025, at 5:15 p.m. Pacific Time. Investors and interested parties can access both live and archived versions of the presentation through the 'Events and Presentations' section on IRADIMED's investor website.
IRADIMED (NASDAQ: IRMD) has achieved the 24th position on Forbes' list of America's Most Successful Small-Cap Companies 2025, improving from its 59th rank in 2024. The company is recognized as the sole provider of non-magnetic IV infusion pump systems and patient vital signs monitoring systems designed for MRI procedures.
Forbes evaluated 914 companies with market values between $300 million and $2 billion, selecting the top 100 based on earnings growth, sales growth, return on equity, and total stock return over both the latest 12 months and five-year periods. The data was compiled as of November 8, 2024.
Roger Susi, President and CEO, attributed this achievement to the company's commitment to innovation, execution of strategic plans, and robust growth resulting in record financial performance.
FAQ
What is the current stock price of Iradimed (IRMD)?
What is the market cap of Iradimed (IRMD)?
